S Kavitha1, M G Sridhar2, S Satheesh3. 1. Department of Biochemistry, PSGIMSR, Tamil Nadu, India. Electronic address: kavie2001@gmail.com. 2. Department of Biochemistry, Jawaharlal Institute of Post Graduate Medical Education and Research, Pondicherry, India. 3. Department of Cardiology, Jawaharlal Institute of Post Graduate Medical Education and Research, Pondicherry, India.
Abstract
AIM: Percutaneous intervention is one of the treatment option for coronary artery disease. Reinfarction and restenosis is one of the complication of the procedure. So this study was conducted to assess plasma fibrinogen levels pre- and post coronary stenting and its relation with outcome. METHODS: After obtaining informed consent, venous blood samples were collected at three timed points in relation to stenting - 24h before, 24h after and 72h after stenting to assess fibrinogen levels. Patients were followed up for six months. Repeat revascularization, myocardial infarction and symptomatic angina were considered as major adverse clinical events. RESULTS: 57 patients who underwent successful stenting and followed up for six months up were included in the study. Mean age was 53 years and 87.7% were males and 29.8% were diabetics. Baseline plasma fibrinogen level was significantly high in patients who developed repeat angina and myocardial infarction after the stenting [288.64±59.43 vs 393.75±32.97mg/dL, p=0.003] and it remained high during serial assessment [322.74±63.92 vs 422.00±55.28mg/dL, 326.23±65.81 vs 419.50±45.82mg/dL, 0.008, 0.012 respectively]. Patients who developed adverse events denied any drug default. CONCLUSION: We conclude that plasma fibrinogen plays a significant role in the development of adverse events following stenting shown by high level of plasma fibrinogen in patients who developed adverse events.
AIM: Percutaneous intervention is one of the treatment option for coronary artery disease. Reinfarction and restenosis is one of the complication of the procedure. So this study was conducted to assess plasma fibrinogen levels pre- and post coronary stenting and its relation with outcome. METHODS: After obtaining informed consent, venous blood samples were collected at three timed points in relation to stenting - 24h before, 24h after and 72h after stenting to assess fibrinogen levels. Patients were followed up for six months. Repeat revascularization, myocardial infarction and symptomatic angina were considered as major adverse clinical events. RESULTS: 57 patients who underwent successful stenting and followed up for six months up were included in the study. Mean age was 53 years and 87.7% were males and 29.8% were diabetics. Baseline plasma fibrinogen level was significantly high in patients who developed repeat angina and myocardial infarction after the stenting [288.64±59.43 vs 393.75±32.97mg/dL, p=0.003] and it remained high during serial assessment [322.74±63.92 vs 422.00±55.28mg/dL, 326.23±65.81 vs 419.50±45.82mg/dL, 0.008, 0.012 respectively]. Patients who developed adverse events denied any drug default. CONCLUSION: We conclude that plasma fibrinogen plays a significant role in the development of adverse events following stenting shown by high level of plasma fibrinogen in patients who developed adverse events.
Authors: Pascalle S Monraats; Jamal S Rana; Aeilko H Zwinderman; Moniek P M de Maat; John P Kastelein; Willem R P Agema; Pieter A F Doevendans; Robbert J de Winter; René A Tio; Johannes Waltenberger; Rune R Frants; Arnoud van der Laarse; Ernst E van der Wall; J Wouter Jukema Journal: Thromb Haemost Date: 2005-03 Impact factor: 5.249
Authors: Braim M Rahel; Frank L J Visseren; Maarten-Jan Suttorp; Thijs H W Plokker; Johannes C Kelder; Bartelt M de Jongh; K Paul Bouter; Rob J A Diepersloot Journal: Cardiovasc Res Date: 2003-10-15 Impact factor: 10.787
Authors: Lawrence Ang; Omid Behnamfar; Samhita Palakodeti; Felice Lin; Ali Pourdjabbar; Mitul P Patel; Ryan R Reeves; Ehtisham Mahmud Journal: J Am Heart Assoc Date: 2017-11-18 Impact factor: 5.501